Single-port thoracoscopic talc pleurodesis for malignant pleural effusion

Year 2018, , 254 - 259, 28.12.2018

Muharrem Özkaya

https://doi.org/10.18663/tjcl.413937

Cited By: 1

Abstract

Aim The aim
of this study was to evaluate the efficacy of single-incision thoracoscopic surgery
(SITS) talc pleurodesis for malignant pleural effusion.

Material and Methods We examined the medical records of all consecutive
patients with malignant pleural effusion who underwent single port
thoracoscopic pleurodesis from 2014 to 2018 at the Health Sciences University
Antalya Practice and Research Center. There were 30 males (54.5%) and 25
females (45.4%), ranging in age from 35 to 88 years (mean age: 64.0 years). Pleurodesis
was achieved by insufflation of 4g of sterile asbestos-free talc; the chest
tube was left in place a minimum of 3 days and was removed when fluid drainage
was less than 100 ml/24 h. Patients were discharged the day after chest tube
removal and a return visit was scheduled on the 30th post-operative day, for
clinical evaluation and for a new chest radiograph. Pleurodesis was regarded as
successful if the amount of the fluid on chest radiograph on the 30th
post-operative day showed a pleural effusion occupying less than one-fourth of
the pleural space.

Results The
main causes of malignant pleural effusion were non-small cell lung carcinoma
and breast cancer. Major symptoms were dyspnea, chest pain and radiographic
findings of pleural fluid. The effusion was on the right side in 40 patients
(72.7%) and on the left side in 15 (27.2%). There was no intraoperative
mortality. The postoperative complication rate was 10.9% (6
patients), and included fever in 1.8% (one patient) and chest pain in 9.0% (5
patients) of the patients. Duration of postoperative pleural drainage ranged
between 3 and 13 days (mean: 3.36 days). The postoperative hospital stay ranged
from 3 to 15 days (mean: 5.6 days). A successful pleurodesis was achieved in 34
of 55 patients (61.8%).

Conclusion SITS talc
pleurodesis is an effective and safe treatment for the
management of malignant pleural effusion.

Keywords

malign, pleural, effusion

Malign plevral efüzyonlarda tek port torakoskopik talk plöredez

Abstract

Aim: The aim of this study was to evaluate the efficacy of single-incision
thoracoscopic surgery (SITS) talc pleurodesis for malignant pleural effusion.

Material and Methods: We examined the medical records of all consecutive
patients with malignant pleural effusion who underwent single port
thoracoscopic pleurodesis from 2014 to 2018 at the Health Sciences University
Antalya Practice and Research Center. Therewere 30 males (54.5%) and 25 females
(45.4%), ranging in age from 35 to 88 years (mean age: 64.0 years). Pleurodesis
was achieved by insufflation of 4g of sterile asbestos-free talc; the chest
tube was left in place a minimum of 3 days and was removedwhen fluid drainage
was less than 100 ml/24 h. Patients were discharged the day after chest tube
removal and a return visit was scheduled on the 30th post-operative day, for
clinical evaluation and for a new chest radiograph. Pleurodesis was regarded as
successful if the amount of the fluid on chest radiograph on the 30th
post-operative dayshowed a pleural effusion occupying less than one-fourth of
the pleural space.

Results: The main causes of malignant pleural effusion were
non-small cell lung carcinoma and breast cancer. Major symptoms were dyspnea,
chest pain and radiographic findings of pleural fluid. The effusion was on the
right side in 40 patients (72.7%) and on the left side in 15 (27.2%). There was
no intraoperative mortality.The postoperative complication rate was 10.9% (6
patients), and includedfever in 1.8% (one patient) and chest pain in 9.0% (5
patients) of the patients.Duration of postoperative pleural drainage ranged
between 3 and 13 days (mean: 3.36 days).The postoperative hospital stay ranged
from 3 to 15 days (mean: 5.6 days). A successful pleurodesis was achieved in 34
of 55 patients (61.8%).

Conclusion:
SITS talc pleurodesis
is an effective and safe treatment for the management of malignant pleural effusion.

Keywords

malign, plevral, efüzyon

References

• [1] Chernow B, Sahn SA. Carcinomatous involvement of the pleura. An analysis of 96 patients. Am J Med 1977;63:695–702.
• [2] Ried M, Hofmann H-S. The treatment of pleural carcinosis with malignant pleural effusion. Dtsch Arztebl Int 2013;110:313–8.
• [3] Sears D, Hajdu SI. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions. Acta Cytol 1987;31:85–97.
• [4] Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ. Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax 2010;65.
• [5] Berlanga LA, Gigirey O. Uniportal video-assisted thoracic surgery for primary spontaneous pneumothorax using a single-incision laparoscopic surgery port: A feasible and safe procedure. Surg Endosc Other Interv Tech 2011;25:2044–7.
• [6] Alar T, Ozcelik C. Single-incision thoracoscopic surgery of pleural effusions for diagnosis and treatment. Surg Endosc Other Interv Tech 2013;27:4333–6.
• [7] Basso SMM, Mazza F, Marzano B, Santeufemia DA, Chiara GB, Lumachi F. Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results. Anticancer Res 2012;32:5131–4.
• [8] Mineo TC, Sellitri F, Tacconi F, Ambrogi V. Quality of Life and Outcomes after Nonintubated versus Intubated Video-Thoracoscopic Pleurodesis for Malignant Pleural Effusion: Comparison by a Case-Matched Study. J Palliat Med 2014;17:761–8.
• [9] Riker D, Sell R. Ultrasound-guided percutaneous biopsy to diagnose indwelling pleural catheter metastasis. J Bronchol Interv Pulmonol 2012;19:165–7.
• [10] Antony VB, Loddenkemper R, Astoul P, Boutin C, Goldstraw P, Hott J, et al. Management of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987–2001.
• [11] Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 2004:CD002916.
• [12] Xia H, Wang XJ, Zhou Q, Shi HZ, Tong ZH. Efficacy and safety of talc pleurodesis for malignant pleural effusion: A meta-analysis. PLoS One 2014;9.
• [13] Bouros D, Antoniou KM, Chalkiadakis G, Drositis J, Petrakis I, Siafakas N. The role of video-assisted thoracoscopic surgery in the treatment of parapneumonic empyema after the failure of fibrinolytics. Surg Endosc Other Interv Tech 2002;16:151–4.
• [14] Jones GR. Treatment of recurrent malignant pleural effusion by iodized talc pleurodesis. Thorax 1969;24:69–73.
• [15] Harley HRS. Malignant pleural effusions and their treatment by intercostal talc pleurodesis. Br J Dis Chest 1979;73:173–7.
• [16] Weissberg D, Ben-Zeev I. Talc pleurodesis. Experience with 360 patients. J Thorac Cardiovasc Surg 1993;106:689–95.
• [17] Hartman DL, Gaither JM, Kesler K a, Mylet DM, Brown JW, Mathur PN. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 1993;105:743-8.
• [18] Yim APC, Chan ATC, Lee TW, Wan IYP, Ho JKS. Thoracoscopic talc insufflation versus talc slurry for symptomatic malignant pleural effusion. Ann Thorac Surg 1996;62:1655–8.
• [19] Aelony Y, King RR, Boutin C. Thoracoscopic talc poudrage in malignant pleural effusions. Chest 1998;113:1007–12.
• [20] Debeljak A, Kecelj P, Triller N, Letonja S, Kern I, Debevec L, et al. Talc pleurodesis: Comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions. J BUON 2006;11:463–7.
• [21] Foroulis CN, Kotoulas C, Konstantinou M et al. The management of malignant pleural effusions: talc pleurodesis versus bleomycin pleurodesis. J BUON 2001;6:397–400.
• [22] Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 2005;128:1431–5.
• [23] Menzies R, Charbonneau M. Thoracoscopy for the diagnosis of pleural disease. Ann Intern Med 1991;114:271–6.
• [24] Arapis K, Caliandro R, Stern JB, Girard P, Debrosse D, Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: Results in 273 patients. Surg Endosc Other Interv Tech 2006;20:919–23.
• [25] De Campos JRM, Vargas FS, De Campos Werebe E, Cardoso P, Teixeira LR, Light RW. Thoracoscopy talc poudrage: A 15-year experience. Chest 2001;119:801–6.